Mihaela Kruger, MD
Interventional Cardiology · North Richland Hills, TXNPI 1881861771
Payments from drug & device makers
Across 275 payments — averaging $23.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$912
- Novartis$792
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$565
- Merck$474
- Amgen$406
- Edwards Lifesciences$356
- plus $3K from 33 others
What the payments were for
- Food & beverage$6,39699%
- Education$791%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 18 | $912 |
| Novartis | 50 | $792 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 25 | $565 |
| Merck | 24 | $474 |
| Amgen | 23 | $406 |
| Edwards Lifesciences | 5 | $356 |
| AstraZeneca | 16 | $293 |
| E.r. Squibb & Sons, L.L.C. | 15 | $272 |
| Abbott | 6 | $250 |
| Boehringer Ingelheim | 12 | $218 |
| Actelion Pharmaceuticals US, Inc. | 6 | $202 |
| Chiesi USA, Inc. | 4 | $188 |
| Penumbra, Inc. | 2 | $137 |
| Novo Nordisk | 6 | $134 |
| Sanofi-aventis U.S. LLC | 7 | $129 |
| Pfizer | 6 | $128 |
| Philips North America LLC | 4 | $121 |
| Boston Scientific | 6 | $119 |
| Esperion Therapeutics, Inc. | 7 | $97 |
| Bayer | 4 | $80 |
| Lilly USA, LLC | 3 | $62 |
| GE HealthCare | 1 | $61 |
| Vital Connect, Inc | 3 | $61 |
| Astellas Pharma US Inc | 3 | $49 |
| Johnson & Johnson | 2 | $43 |
| Azurity Pharmaceuticals, Inc. | 2 | $34 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $32 |
| Itamar Medical Inc | 1 | $32 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Nuwellis, Inc. | 1 | $26 |
| Cashflow Solutions, LLC | 2 | $24 |
| Lexicon Pharmaceuticals, Inc. | 1 | $23 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Osprey Medical Inc | 1 | $21 |
| Bardy Diagnostics, Inc. | 1 | $20 |
| Biotronik Inc. | 1 | $18 |
| Atricure, Inc. | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $16 |
| Elutia, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,475 in reported general payments places this provider in the 30th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 205 | $237,556 |
| JardianceEmpagliflozin | 131 | $160,659 |
| EntrestoSacubitril/Valsartan | 88 | $130,930 |
| Repatha SureclickEvolocumab | 111 | $87,907 |
| FarxigaDapagliflozin Propanediol | 49 | $63,511 |
| XareltoRivaroxaban | 65 | $61,782 |
| MounjaroTirzepatide | 38 | $43,846 |
| NexletolBempedoic Acid | 21 | $16,215 |
| Praluent PenAlirocumab | 13 | $5,932 |
| Rosuvastatin Calcium | 351 | $3,522 |
| Metoprolol Succinate | 280 | $3,008 |
| Atorvastatin Calcium | 205 | $2,102 |
| Carvedilol | 247 | $1,968 |
| Ezetimibe | 110 | $1,923 |
| Losartan Potassium | 190 | $1,791 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $128 | $237,556205 claims |
| Boehringer IngelheimJardiance | $218 | $160,659131 claims |
| NovartisEntresto | $792 | $130,93088 claims |
| AstraZenecaFarxiga | $293 | $63,51149 claims |
| Johnson & JohnsonXarelto | $43 | $61,78265 claims |
| Lilly USA, LLCMounjaro | $62 | $43,84638 claims |
| Esperion Therapeutics, Inc.Nexletol | $97 | $16,21521 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in North Richland Hills
- Robert StolerDallas$8.2M
- James ChoiDallas$5.2M
- Srinivasa PotluriPlano$5.1M
- Neal KleimanHouston$4.8M
- Juan GranadaHouston$4.3M
- Ira LieberKingwood$3.3M
- Cara Ann EastDallas$3M
- Abhijeet DhobleHouston$2.7M
- Jeffrey CarrTyler$2.7M
- M Asad KarimMcKinney$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.